Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, Parambir S., Singh, Siddharth, Patel, Janki, Soni, Meera, Prokop, Larry J., Younossi, Zobair, Sebastiani, Giada, Ekstedt, Mattias, Hagstrom, Hannes, Nasr, Patrik, Stal, Per, Wong, Vincent Wai‐Sun, Kechagias, Stergios, Hultcrantz, Rolf, Loomba, Rohit·2017·Hepatology
DOI 10.1002/hep.29085

Cited by (1,004)

Items 301–400 of 1,004

  1. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
    Goyal, Omesh, Nohria, Sahil, Goyal, Prerna, Kaur, Jaskirat, Sharma, Sarit, Sood, Ajit, Chhina, Rajoo Singh · 2020 · Scientific Reports
  2. Nonsteroidal FXR Ligands: Current Status and Clinical Applications
    Gege, Christian, Hambruch, Eva, Hambruch, Nina, Kinzel, Olaf, Kremoser, Claus · 2019 · Handbook of Experimental Pharmacology
  3. Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk
    Mohammad Shafi Kuchay, José Ignacio Martínez‐Montoro, Parjeet Kaur, José Carlos Fernández‐García, Bruno Ramos‐Molina · 2022 · Ageing Research Reviews
  4. Busting the myth of methotrexate chronic hepatotoxicity
    Vincent Di Martino, Delphine Weil, Frank Verhoeven, François Aubin, Jérôme Avouac, Lucine Vuitton, Frédéric Lioté, Thierry Thévenot, Daniel Wendling · 2022 · Nature Reviews Rheumatology
  5. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
    Mazen Noureddin, Juan P. Frías, Guy W. Neff, K Jean Lucas, Cynthia A. Behling, Pierre Bédossa, Julie Dubourg, Doreen C. Chan, Mark Burch, Erica Fong et al. · 2025 · The Lancet
  6. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study
    Satoshi Oeda, Hirokazu Takahashi, Kento Imajo, Yuya Seko, Yuji Ogawa, Michihisa Moriguchi, Masato Yoneda, Keizo Anzai, Shinichi Aishima, Masayoshi Kage et al. · 2019 · Journal of Gastroenterology
  7. Screening for therapeutic trials and treatment indication in clinical practice: MACK ‐3, a new blood test for the diagnosis of fibrotic NASH
    Jérôme Boursier, Rodolphe Anty, Luisa Vonghia, V. Moal, Thomas Vanwolleghem, Clémence M. Canivet, S. Michalak, Stéphanie Bonnafous, Peter P. Michielsen, Frédéric Oberti et al. · 2018 · Alimentary Pharmacology & Therapeutics
  8. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016
    Donghee Kim, Won Kyum Kim, Adeyinka Adejumo, George T. Cholankeril, Sean P. Tighe, Robert J. Wong, Stevan A. Gonzalez, Stephen A. Harrison, Zobair M. Younossi, Aijaz Ahmed · 2019 · Hepatology International
  9. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
    Amalia Gastaldelli, Enrico Repetto, Cristian Guja, Elise Hardy, Jenny Han, Serge A Jabbour, Ele Ferrannini · 2019 · Diabetes Obesity and Metabolism
  10. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
    Arun Jayant Sanyal, Lei Ling, Ulrich H. Beuers, Alex M. DePaoli, Hsiao Dee Lieu, Stephen A. Harrison, Gideon Morris Hirschfield · 2021 · JHEP Reports
  11. Recent advances in nonalcoholic fatty liver disease metabolomics
    Hwi Young Kim · 2021 · Clinical and Molecular Hepatology
  12. Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
    Zobair M. Younossi, Linda L Henry · 2024 · Diabetes Spectrum
  13. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Yejin Kim, Yoosoo Chang, Yong Kyun Cho, Jiin Ahn, Ho Cheol Shin, Seungho Ryu · 2018 · Clinical Gastroenterology and Hepatology
  14. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
    Zobair M. Younossi, Maria Stepanova, Arun Jayant Sanyal, Stephen A. Harrison, Vlad Ratziu, Manal F. Abdelmalek, Anna Mae Diehl, Stephen Hugh Caldwell, Mitchell L. Shiffman, Raul Aguilar Schall et al. · 2018 · Journal of Hepatology
  15. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
    Ahmad Moolla, Kenzo Motohashi, Thomas Marjot, Amelia Shard, Mark Andrew Ainsworth, Alastair McIntosh Gray, Rury R. Holman, Michael Pavlides, John Denis Ryan, Jeremy Tomlinson et al. · 2019 · Frontline Gastroenterology
  16. Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model
    Mohamed Elbadawy, Megumi Yamanaka, Yuta Goto, Kimika Hayashi, Ryouichi Tsunedomi, Shoichi Hazama, Hiroaki Nagano, Toshinori Yoshida, Makoto Shibutani, Ryo Ichikawa et al. · 2020 · Biomaterials
  17. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease
    Michelle T. Long, Sanil Gandhi, Rohit Seth Loomba · 2020 · Metabolism
  18. An update on the recent advances in antifibrotic therapy
    Frank Tacke, Ralf Weiskirchen · 2018 · Expert Review of Gastroenterology & Hepatology
  19. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
    Sven Francque, Pierre Bédossa, Manal F. Abdelmalek, Quentin Mark Anstee, Elisabetta Bugianesi, Vlad Ratziu, Philippe Huot-Marchand, Scherrer Bruno, Jean‐Louis Junien, Pierre Broqua et al. · 2020 · Contemporary Clinical Trials
  20. Role of Ultrasound Methods for the Assessment of NAFLD
    Golo Petzold · 2022 · Journal of Clinical Medicine
  21. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
    Jinku Kang, Jorge Postigo, KyeongJin Kim, Changyu Zhu, Junjie Yu, Marica Meroni, Brent Mayfield, Alberto Bartolomé, Dianne H. Dapito, Anthony W. Ferrante et al. · 2023 · JCI Insight
  22. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
    Amanda C. Cheung, Brent A. Neuschwander‐Tetri, David Erwin Kleiner, Elmer Schabel, Mary Eugenia Rinella, Stephen A. Harrison, Vlad Ratziu, Arun Jayant Sanyal, Rohit Seth Loomba, Sophie Jeannin Megnien et al. · 2019 · Hepatology
  23. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
    David Niederseer, Bernhard Wernly, Elmar Stephan Aigner, Felix Stickel, Christian Datz · 2021 · Journal of Clinical Medicine
  24. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
    Stuart McPherson, Matthew J Armstrong, Jeremy F Cobbold, Lynsey Corless, Quentin Mark Anstee, Richard Aspinall, Stephen T Barclay, Paul N Brennan, Tessa M. Cacciottolo, Robert David Goldin et al. · 2022 · The Lancet. Gastroenterology & hepatology
  25. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy
    Rocío Gallego‐Durán, Anna Hadjihambi, Javier Ampuero, Christopher F. Rose, Rajiv Jalan, Manuel Romero‐Gómez · 2024 · Nature Reviews Gastroenterology & Hepatology
  26. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
    Siyer Roohani, Frank Tacke · 2021 · International Journal of Molecular Sciences
  27. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis
    Ann Jane Archer, K. Belfield, James G. Orr, Fiona H. Gordon, Kushala W. M. Abeysekera · 2022 · Frontline Gastroenterology
  28. Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
    Jinghua Peng, Jing Leng, Huajie Tian, Tao Yang, Yi Fang, Qin Feng, Yu Zhao, Yiyang Hu · 2018 · Frontiers in Pharmacology
  29. A critical review of endpoints for non-cirrhotic NASH therapeutic trials
    Ratziu, Vlad · 2018 · Journal of Hepatology
  30. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study
    Yoosoo Chang, Yong Kyun Cho, Juhee Cho, Hyun-Suk Jung, Kyung Eun Yun, Jiin Ahn, Chong Il Sohn, Ho Cheol Shin, Seungho Ryu · 2019 · The American Journal of Gastroenterology
  31. Adipocytokines: Are they the Theory of Everything?
    Pierre Maximus, Zeina Al Achkar, Pousette Hamid, Syeda S. Hasnain, Cesar Peralta · 2020 · Cytokine
  32. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care
    Preya J. Patel, Fabrina Hossain, L. Horsfall, X. Banh, K. Hayward, Suzanne Williams, T. Johnson, A. Bernard, N. Brown, G. Lampe et al. · 2018 · Hepatology Communications
  33. Hepatocellular carcinoma and non-alcoholic fatty liver disease
    Pegah Golabi, Logan P. Rhea, Linda L Henry, Zobair M. Younossi · 2019 · Hepatology International
  34. Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study
    Mark G. Swain, Alnoor S. Ramji, Keyur Patel, Giada Sebastiani, Abdel Aziz Shaheen, Edward Tam, Paul Marotta, Magdy Elkhashab, HARPREET SINGH BAJAJ, Chris Estes et al. · 2020 · CMAJ Open
  35. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
    Zobair M. Younossi, Sean C. Felix, Thomas Jeffers, Elena Younossi, Fatema Nader, Huong Pham, Arian Afendy, Rebecca Cable, Andrei Racila, Zahra Younoszai et al. · 2021 · JAMA Network Open
  36. The association of hepatic steatosis and fibrosis with heart failure and mortality
    Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You‐Bin Lee, Sang‐Man Jin, Kyu Yeon Hur, Jae Hyeon Kim · 2021 · Cardiovascular Diabetology
  37. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency
    Limin Liu, Qingsong Fu, Tiantian Li, Kai Shao, Xing Zhu, Yingzi Cong, Xiaoyun Zhao · 2022 · PLoS ONE
  38. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
    Zobair M. Younossi · 2017 · Liver Transplantation
  39. Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis
    Yoosoo Chang, Seungho Ryu, Yejin Kim, Yong Kyun Cho, Eunju Sung, Han‐Na Kim, Jiin Ahn, Hyun Suk Jung, Kyung Eun Yun, Seolhye Kim et al. · 2019 · Hepatology
  40. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
    Eda Kaya, Alev Bakır, Haluk Tarık Kani, Coşkun Özer Demirtaş, Çağlayan Keklikkıran, Yusuf Nadir Yilmaz · 2019 · Gut and Liver
  41. A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD
    Tien Sy Dong, William R. Katzka, Venu Lagishetty, Kayti Luu, Meg Hauer, Joseph R. Pisegna, Jonathan P. Jacobs · 2020 · Scientific Reports
  42. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
    Joost P.H. Drenth, Jörn Markus Schattenberg · 2020 · Expert Opinion on Investigational Drugs
  43. Exercise Intervention Mitigates Pathological Liver Changes in NAFLD Zebrafish by Activating SIRT1/AMPK/NRF2 Signaling
    Yunyi Zou, Zhanglin Chen, Chen‐Chen Sun, Dong Kwon Yang, Zuoqiong Zhou, Xiyang Peng, Lan Zheng, Chenhao Tang · 2021 · International Journal of Molecular Sciences
  44. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
    Gwyneth Shook Ting Soon, Aileen Wee · 2020 · Clinical and Molecular Hepatology
  45. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population
    Yochai Schonmann, Hanny Yeshua, Itay Bentov, Shira Zelber‐Sagi · 2020 · Digestive and Liver Disease
  46. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
    Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2021 · Life
  47. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
    Michael P. Cooreman, Javed Butler, Robert Patrick Giugliano, Faiez M. Zannad, Lucile Dzen, Philippe Huot-Marchand, Martine Baudin, Daniel R. Beard, Jean‐Louis Junien, Pierre Broqua et al. · 2024 · Nature Communications
  48. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease
    Tamaki, Nobuharu, Ahlholm, Noora, Luukkonen, Panu K., Porthan, Kimmo, Sharpton, Suzanne R., Ajmera, Veeral, Kono, Yuko, Dave, Shravan, Ahmed, Aijaz, Sundaram, Vinay et al. · 2022 · Journal of Clinical Investigation
  49. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
    Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuji Ogawa, Yuichiro Eguchi, Yoshio Sumida, Masashi Yoneda, Miwa Kawanaka, Satoru Saito, Katsutoshi Tokushige et al. · 2017 · Journal of Gastroenterology
  50. Circulating microbiota-derived metabolites: a “liquid biopsy?
    Gemma Aragonès, Marina Colom‐Pellicer, Carmen Aguilar, Esther Guiu‐Jurado, Salomé Martínez, Fàtima Sabench, José Antonio Porras, David Riesco, Daniel Del Castillo, Cristóbal Richart et al. · 2019 · International Journal of Obesity
  51. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
    Alejandro Campos-Murguía, Astrid Ruiz‐Margáin, José Alberto González-Regueiro, Ricardo Ulises Macías‐Rodríguez · 2020 · World Journal of Gastroenterology
  52. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Ying Qu, Yanyan Song, Chengwei Chen, Qingchun Fu, Junping Shi, Yun Xu, Qing Xie, Yongfeng Yang, Yongjian Zhou, Liang-Ping Li et al. · 2021 · Clinical and Translational Gastroenterology
  53. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease
    Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Yoshie Itakura, Kento Inada, Sakura Kirino, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa et al. · 2021 · Journal of Gastroenterology and Hepatology
  54. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
    Axel Wester, Ying Shang, Emilie Toresson Grip, Anthony Matthews, Hannes Hagström · 2024 · Gut
  55. Prevalence of at‐risk MASH , M et ALD and alcohol‐associated steatotic liver disease in the general population
    Carolin Victoria Schneider, Kai Markus Schneider, Anastasia Artemis Raptis, Helen Ye Rim Huang, Christian Trautwein, Rohit Seth Loomba · 2024 · Alimentary Pharmacology & Therapeutics
  56. Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
    Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Seth Loomba, Namiki Izumi · 2024 · Alimentary Pharmacology & Therapeutics
  57. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach
    Ivica Grgurević, Kristian Podrug, Ivana Mikolašević, Michał Kukla, Anita Madir, Emmanuel A. Tsochatzis · 2020 · Canadian Journal of Gastroenterology and Hepatology
  58. Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice
    Shrirang Inamdar, Ankita Joshi, Sajad Malik, Ramanamurthy Boppana, Saroj Ghaskadbi · 2019 · Biochemical and Biophysical Research Communications
  59. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
    Alessandro Federico, Marcello Dallio, Mario Masarone, Antonietta Gerarda Gravina, Rosa Di Sarno, Concetta Tuccillo, Valentina Cossiga, Stefania Lama, Paola Stiuso, Filomena Morisco et al. · 2019 · Oxidative Medicine and Cellular Longevity
  60. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
  61. Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease
    Cyrielle Caussy, Jun Chen, Mosab H. Alquiraish, Sandra Cepin, Phirum Nguyen, Carolyn Hernandez, Meng Yin, Ricki Bettencourt, Edward R. Cachay, Saumya Jayakumar et al. · 2018 · Clinical Gastroenterology and Hepatology
  62. Review article: new treatments in non‐alcoholic fatty liver disease
    Sarah Ann Townsend, Philip Noel Newsome · 2017 · Alimentary Pharmacology & Therapeutics
  63. Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition
    Zobair M. Younossi · 2018 · Hepatology
  64. Burden of Disease due to Nonalcoholic Fatty Liver Disease.
    M. Muthiah, A. Sanyal · 2020 · Gastroenterology Clinics of North America
  65. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review
    Ying Peng, Qinglin Wei, Yonghong He, Qiaoling Xie, Yanchao Liang, Liangjun Zhang, Yiju Xia, Yan Li, Wensheng Chen, Jingjing Zhao et al. · 2020 · Expert Review of Gastroenterology & Hepatology
  66. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
    Stine, Jonathan G., Schreibman, Ian R., Faust, Alison J., Dahmus, Jessica, Stern, Benjamin, Soriano, Christopher, Rivas, Gloriany, Hummer, Breianna, Kimball, Scot R., Geyer, Nate R. et al. · 2022 · Hepatology
  67. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
    MICHAEL S. HENDRYX, Yi Dong, Jonas M. Ndeke, Juhua Luo · 2022 · PLoS ONE
  68. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
    Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke · 2020 · Expert Opinion on Pharmacotherapy
  69. Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden
    Gabriel Issa, Ying Shang, Rickard Strandberg, Hannes Hagström, Axel Wester · 2025 · Journal of Hepatology
  70. Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease
    Scott A. Mchenry, Yikyung Park, Jeffrey D. Browning, Gregory S. Sayuk, Nicholas O. Davidson · 2020 · Clinical Gastroenterology and Hepatology
  71. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population
    Daniel Ferraz de Campos Mazo, Fernanda de Mello Malta, José Tadeu Stefano, Ana Paula Moreira Salles, Michele Soares Gomes‐Gouvêa, Ana Catharina de Seixas Santos Nastri, Jazon Romilson Souza Almeida, João Renato Rebello Pinho, Flair José Carrilho, Claudia Pinto Marques Souza de Oliveira · 2019 · Annals of Hepatology
  72. Understanding Dietary Intervention-Mediated Epigenetic Modifications in Metabolic Diseases
    Shaza Asif, Nadya M. Morrow, Erin E. Mulvihill, Kyoung-Han Kim · 2020 · Frontiers in Genetics
  73. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD‐NASH Cohort
    Marian Troelstra, Julia J. Witjes, Anne‐Marieke van Dijk, Anne Linde Mak, Oliver J. Gurney‐Champion, Jurgen Henk Runge, Diona Zwirs, Daniela Stols‐Gonçalves, Aelko H. Zwinderman, Marije ten Wolde et al. · 2021 · Journal of Magnetic Resonance Imaging
  74. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
    Maral Amangurbanova, Daniel Q. Huang, Rohit Seth Loomba · 2022 · Alimentary Pharmacology & Therapeutics
  75. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
    Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young‐Joo Jin, Seung‐seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim et al. · 2024 · Clinical and Molecular Hepatology
  76. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
    Noboru Kurinami, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Fumio MIYAMOTO, Keizo Kajiwara, Katsunori Jinnouch, Tomio Jinnouchi, Hideaki Jinnouchi · 2018 · Diabetes Research and Clinical Practice
  77. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology
    Yusuf Nadir Yilmaz, Fatih Eren · 2018 · European Journal of Gastroenterology & Hepatology
  78. Non‐alcoholic fatty liver disease increases the risk of incident chronic kidney disease
    Leonard Kaps, Christian Labenz, Peter R. Galle, Julia Weinmann‐Menke, Karel Kostev, Jörn Markus Schattenberg · 2020 · United European Gastroenterology Journal
  79. Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
    Vandel, Jimmy, Dubois‐Chevalier, Julie, Gheeraert, Céline, Derudas, Bruno, Raverdy, Violetta, Thuillier, Dorothée, Gaal, Luc, Francque, Sven, Pattou, François, Staels, Bart et al. · 2021 · Hepatology
  80. Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis
    Yoshio Sumida, Takeshi Okanoue, Atsushi Nakajima, Japan Study Group of NAFLD (JSG‐NAFLD) · 2019 · Hepatology Research
  81. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
    Andreas Drolz, Stefan Wolter, Malte H. Wehmeyer, Felix Piecha, Thomas Horvatits, Julian Schulze zur Wiesch, Ansgar Wilhelm Lohse, Oliver Mann, Johannes Kluwe · 2021 · International Journal of Obesity
  82. Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study
    Yoo Jin Um, Yoosoo Chang, Hyun Suk Jung, In Young Cho, Jun Ho Shin, Ho Cheol Shin, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu · 2021 · Clinical and Translational Gastroenterology
  83. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
    Jung Hwan Yu, Han Ah Lee, Seung Up Kim · 2022 · Clinical and Molecular Hepatology
  84. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic
    CLAUDIA M. FILOZOF, Shein‐Chung Chow, Lara Dimick‐Santos, Yeh‐Fong Chen, Richard N. Williams, Barry J. Goldstein, Arun Jayant Sanyal · 2017 · Hepatology Communications
  85. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
    György Baffy · 2018 · Digestive Diseases and Sciences
  86. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
    Jeffrey Thomas Budd, Kenneth J. Cusi · 2020 · The American Journal of Medicine
  87. Magnetic resonance elastography plus Fibrosis‐4 versus FibroScan–aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH‐related fibrosis
    Nobuharu Tamaki, Kento Imajo, Suzanne R. Sharpton, Jinho Jung, Nobuyoshi Kawamura, Masato Yoneda, Mark A. Valasek, Cynthia A. Behling, Claude B. Sirlin, Atsushi Nakajima et al. · 2021 · Hepatology
  88. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
    Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q. Huang, Rohit Seth Loomba · 2022 · Hepatology Research
  89. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
    Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, Marjo J. E. Campmans-Kuijpers, Vincenzo Cardinale, Irit Chermesh, Ahad Eshraghian, Haluk Tarık Kani, Wafaa Khannoussi, L. Lacaze et al. · 2022 · Clinical Nutrition
  90. Clinical relevance of liver histopathology and different histological classifications of NASH in adults
    F. Nascimbeni, S. Ballestri, M. Machado, A. Mantovani, H. Cortez-Pinto, G. Targher, A. Lonardo · 2018 · Expert Review of Gastroenterology & Hepatology
  91. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment
    Shunsuke Mori, Nobuyuki Arima, Masahiro Ito, Shigetoshi Fujiyama, Yasuhiro Kamo, Yukitaka Ueki · 2018 · PLoS ONE
  92. Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis
    Puengel, Tobias, Lefere, Sander, Hundertmark, Jana, Kohlhepp, Marlene, Penners, Christian, Van de Velde, Frederique, Lapauw, Bruno, Hoorens, Anne, Devisscher, Lindsey, Geerts, Anja et al. · 2022 · International Journal of Molecular Sciences
  93. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis
    Jee‐Fu Huang, Pei‐Chien Tsai, Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Meng‐Hsuan Hsieh, Chia‐Yen Dai, Jeng‐Fu Yang, Shinn‐Cherng Chen, Ming‐Lung Yu et al. · 2019 · Journal of the Formosan Medical Association
  94. Sex-related association of nonalcoholic fatty liver disease and liver fibrosis with body fat distribution in the general US population
    Stefano Ciardullo, Alice Oltolini, Rosa Cannistraci, Emanuele Muraca, Gianluca Perseghin · 2022 · American Journal of Clinical Nutrition
  95. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease
    Mariangela Allocca, Gionata Fiorino, Cristiana Bonifacio, Laurent Peyrin‐Biroulet, Silvio Danese · 2019 · Clinical Gastroenterology and Hepatology
  96. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
    Jeffrey Thomas Budd, Kenneth J. Cusi · 2020 · Current Diabetes Reports
  97. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
    van Koppen, Arianne, Verschuren, Lars, van den Hoek, Anita M., Verheij, Joanne, Morrison, Martine C., Li, Kelvin, Nagabukuro, Hiroshi, Costessi, Adalberto, Caspers, Martien P.M., van den Broek, Tim J. et al. · 2018 · Cellular and Molecular Gastroenterology and Hepatology
  98. Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma
    Dawei Chen, Chenyue Zhang, Jiamao Lin, Xinyu Song, Haiyong Wang · 2018 · Cancer Management and Research
  99. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
    Yasaman Vali, Jenny Lee, Jérôme Boursier, René Spijker, Joanne Verheij, M. Julia Brosnan, Quentin Mark Anstee, Patrick M. Bossuyt, Mohammad Hadi Zafarmand, on behalf of the LITMUS Systematic Review Team · 2021 · Journal of Clinical Medicine
  100. Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah‐Kheong Chan · 2022 · Clinical and Molecular Hepatology